Compass therapeutics reports 2023 financial results and provides corporate update

Enrollment in companion-002, the phase 2/3 randomized study of ctx-009 (dll4 x vegf-a bispecific antibody) in patients with advanced biliary tract cancer (btc), continues to progress well; top-line data from this study are expected by the end of 2024. enrollment in companion-003, the phase 2 study of ctx-009 in patients with advanced colorectal cancer (crc) was completed in the first quarter of 2024; top-line data from stage 1 of this study are expected by mid-year 2024.
CMPX Ratings Summary
CMPX Quant Ranking